Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 20/20 | 1.00 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.61 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | PDE5A | O76074 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12401082 | 0.99 | PDE9A (0.98) | PDE9APDE1CPDE1B | |
| SCHEMBL7882627 | 0.90 | PDE9A (0.82) | PDE9APDE1C | |
| SCHEMBL7888328 | 0.90 | PDE9A (0.82) | PDE9APDE1C | |
| SCHEMBL12401030 | 0.90 | PDE9A (0.81) | PDE9APDE1CPDE1BPDE5A | |
| SCHEMBL7890345 | 0.89 | PDE9A (0.79) | PDE9APDE1CPDE1B | |
| SCHEMBL7989552 | 0.89 | PDE9A (0.79) | PDE9APDE1CPDE1B | |
| SCHEMBL12401124 | 0.89 | PDE9A (0.80) | PDE9APDE1CPDE1B | |
| SCHEMBL12401048 | 0.88 | PDE9A (0.79) | PDE9APDE1CPDE1BPDE5A | |
| SCHEMBL7886923 | 0.86 | PDE9A (0.76) | PDE9APDE1CPDE1B | |
| SCHEMBL2528553 | 0.84 | PDE9A (0.73) | PDE9APDE1CPDE1BPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017070293-A1 | PHOSPHODIESTERASE 9 INHIBITOR AND LEVODOPA THERAPY | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| US-8741907-B2 | Alkyl-substituted pyrazolopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-8741907-B2 | Alkyl-substituted pyrazolopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-8741907-B2 | Alkyl-substituted pyrazolopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-20110294834-A1 | Alkyl-substituted pyrazolopyrimidines | HENDRIX MARTIN (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294834-A1 | Alkyl-substituted pyrazolopyrimidines | HENDRIX MARTIN (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294834-A1 | Alkyl-substituted pyrazolopyrimidines | HENDRIX MARTIN (DE) | 2011-12-01 | — | — | US | disclosed |
| US-8039477-B2 | Substituted pyrazolo[3,4-d]pyrimidin-4-one compounds as phosphodiesterase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-18 | — | — | US | disclosed |
| US-8039477-B2 | Substituted pyrazolo[3,4-d]pyrimidin-4-one compounds as phosphodiesterase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-18 | — | — | US | disclosed |
| US-8039477-B2 | Substituted pyrazolo[3,4-d]pyrimidin-4-one compounds as phosphodiesterase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-18 | — | — | US | disclosed |
| US-20060111372-A1 | Alkyl-substituted pyrazolopyrimidines | BAYER HEALTHCARE AG (DE) | 2006-05-25 | — | — | US | disclosed |
| EP-1534713-B1 | ALKYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2006-01-11 | — | — | EP | disclosed |
| EP-1534713-A1 | ALKYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | Bayer HealthCare AG (DE) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004026876-A1 | ALKYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294834-A1 | Alkyl-substituted pyrazolopyrimidines | P2RX4, P2RX5, P2RY4 | PDE9A 450/4885PDE1C 753/4885PDE1B 342/4885 |
| US-20060111372-A1 | Alkyl-substituted pyrazolopyrimidines | P2RX4, P2RX5, P2RY4 | PDE9A 450/4885PDE1C 753/4885PDE1B 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.